Product Code: PHM272A
Highlights:
The global market for epigenetic therapeutics is estimated to increase from $6.8 billion in 2023 to reach $9.8 billion by 2028, at a compound annual growth rate (CAGR) of 7.7% from 2023 through 2028.
The global market for epigenetic therapeutics for PRAP inhibitors is estimated to increase from $3.4 billion in 2023 to reach $5.2 billion by 2028, at a CAGR of 8.6% from 2023 through 2028.
The global market for epigenetic therapeutics for kinase inhibitors is estimated to increase from $2.6 billion in 2023 to reach $3.7 billion by 2028, at a CAGR of 7.6% from 2023 through 2028.
Report Scope:
This report is a comprehensive study of the global market for epigenetic therapeutics. It describes the epigenetic therapeutics market, which is segmented by product type and region. Based on product type, the market is segmented into PRAP inhibitors, Kinase inhibitors, IDH inhibitors, HDAC inhibitors, DNMT inhibitors and KMT inhibitors. The market is segmented by region into North America, Latin America, Europe, Asia-Pacific, and the Rest of the World (RoW).
This report examines the factors driving growth in the epigenetic drugs market, and it reviews major players, established companies and new entrants.
This report, however, does not cover epigenetic diagnostic assays and instruments.
Report Includes:
- 77 tables
- A comprehensive overview of the global markets for epigenetic therapeutics
- Analyses of the global market trends with historical market revenue data (sales figures) for 2020-2022, estimates for 2023, and projections of compound annual growth rates (CAGRs) through 2028
- Understanding of the upcoming market potential for epigenetic therapeutics with an emphasis on new products and technologies, and areas of focus to forecast this market into various segments and sub-segments
- Estimation of the actual market size and revenue forecast for the global epigenetic therapeutics market, and corresponding market share analysis product type and region
- In-depth information (facts and figures) concerning major market dynamics (DROs), technology advancements, new products and applications in epigenomics, and COVID-19 impact on the industry
- Coverage of the technological, economic, and business considerations of the market for epigenetic therapeutics, with analyses and growth forecasts through 2028
- A look at the recent breakthrough innovations, key technological issues, market regulations, and current status on the intellectual property rights on epigenetic therapeutics
- Review of patent trends and research publications for innovations in the genome-editing technologies
- Insight into the recent industry structure, government regulations and policies, development issues, and the vendor landscape
- Analysis of the competitive environment and market opportunities based on the company's business strategies, product mapping, and operational integration
- Descriptive company profiles of the leading pharma corporations, including AstraZeneca, Bristol-Myers Squibb, GSK, Ipsen, Seagen, and Incyte
Table of Contents
Chapter 1 Introduction
- Study Goals and Objectives
- Reasons for Doing this Study
- Scope of Report
- Methodology
- Information Sources
- Geographic Breakdown
- Analyst's Credentials
- BCC Custom Research
- Related BCC Research Reports
Chapter 2 Summary and Highlights
- Highlights of the Market for Epigenetic Therapeutics
Chapter 3 Market Overview and Definitions
Chapter 4 Market Trends
- Market Drivers
- Aging Population
- Risk of Cancer in Major Countries
- Penetration of Targeted Medicine in Emerging Markets
- Market Opportunity
- Market Restraints
Chapter 5 Market Breakdown by Product Type
- Introduction
- PRAP Inhibitors
- Kinase Inhibitors
- IDH Inhibitors
- HDAC Inhibitors
- DNMT Inhibitors
- KMT Inhibitors
Chapter 6 Impact of COVID-19
- Introduction
- Impact of COVID-19 on the Medical Devices and Pharmaceutical Industries
- Decline/Delay in Elective Procedures
- Impact of COVID-19 on Medical Device and Pharmaceutical Product Segments
- Impact of COVID-19 on Epigenetic Therapeutics Markets
Chapter 7 Market Breakdown by Region
- Market Overview and Discussion
- North America
- Latin America
- Europe
- Asia-Pacific
- Rest of the World
Chapter 8 Emerging/Upcoming Technologies
- CRISPR
- Antibody Drug Conjugates
- Multitargeting Agents
Chapter 9 Competitive Landscape
- Industry Scenario
- Company Shares
Chapter 10 Patent Analysis
- Patent Analysis, by Manufacturer
Chapter 11 Pipeline Analysis
Chapter 12 Company Profiles
- ASTRAZENECA
- BRISTOL-MYERS SQUIBB
- CLOVIS ONCOLOGY
- GSK PLC
- INCYTE
- IPSEN
- SEAGEN
- SERVIER LABORATORIES, LTD.
Chapter 13 Appendix: Acronyms